05 Nov, 2022 12-Month Results from ILLUMINATE-C Phase 3 Study of OXLUMO® (lumasiran) and Phase 2 Study of Investigational Cemdisiran Presented at ASN Kidney Week
During the American Society of Nephrology (ASN) Kidney Week, we presented new 12-month results from the ILLUMINATE-C Phase 3 study of lumasiran in patients of all ages with primary hyperoxaluria type 1 (PH1) and advanced kidney disease. Additional research was presented on the development and validation of a novel assay to determine oxalate concentration in plasma.
Frishberg, et al. “Lumasiran for Patients with Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 12-Month Analysis of the Phase 3 ILLUMINATE-C Trial”
Clausen, et al. “Quantification of Oxalate in Human Plasma by Novel Liquid Chromatography—Tandem Mass Spectrometry: Method Development, Validation, and Application in Lumasiran Clinical Trials”
We also presented new results from the Phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway that is being developed in collaboration with Regeneron Pharmaceuticals for the treatment of immunoglobulin A nephropathy.
